Low-pH preconditioned macrophage-derived extracellular vesicles enable targeted and enhanced paclitaxel therapy in gastric cancer

Figure 5 In vivo anti-tumor efficacy of PTX@LP-EV in MKN45 xenograft models. A: Schematic of the therapeutic regimen in MKN45 tumor-bearing nude mice; B: Tumor growth curves of mice treated with PBS, low-pH preconditioned macrophage-derived extracellular vesicles (LP-EV), free paclitaxel (PTX), or PTX@LP-EV; C: Final tumor weights measured at the end of the experiment; D: Representative images of immunohistochemical staining for Ki-67 and cleaved caspase-3, and TUNEL staining of tumor sections. Data in (C) represent means ± SD. Statistical significance was tested using one-way ANOVA with multiple comparison tests, ^dP < 0.0001. LP-EV: Low-pH preconditioned macrophage-derived extracellular vesicle; PTX: Paclitaxel.